肿瘤细胞治疗研究
FRONTIER PAPERS
Erratum to "CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic leukemia using a Coccidioides immitis-derived group II intron pl
Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models.
降低化疗后的复发率仍是提高肿瘤治疗疗效的一大挑战。
Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-ta
复发仍是儿童 B 细胞急性淋巴细胞白血病（B-ALL）治疗失败和死亡的主要原因。
CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic Leukemia using a Coccidioides immitis-derived group II intron platform.
这些结果支持基于circRNA的CAR-NK疗法作为提高癌症免疫治疗安全性和有效性的一种有效方法的潜力。
Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside.
作为开创性的免疫治疗手段，CAR-T 细胞与NK 细胞（CAR-NK）疗法在治疗多种血液系统恶性肿瘤时已显示出显著的临床疗效。
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a pha
Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signat
我们的研究突出了15 21 CAR-NK细胞的内在优势及外在T细胞协同获益，为基于NK细胞的免疫疗法提供了一种有前景的策略。
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.
CD19-BBz CAR-NK 细胞可行且治疗上安全，能够在 B 细胞淋巴瘤患者中诱导持久缓解。
Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways.
与共表达 IL-15 的 CAR-NK 细胞相比，共表达 IL-21 的 CAR-NK 细胞在响应 CD19 + Raji 淋巴瘤细胞时，IFN-、TNF- 和 Granzyme B 的产生以及脱颗粒均显著增加，从而在反复肿瘤刺激下表现出增强的细胞毒活性。
Constitutive RLI Armoring Enhances CAR-NK Cell Effector Functions but Causes Lethal Toxicity In Vivo.
本研究表明，组成型IL15装甲化可以是一种增强CAR-NK细胞的有效但有风险的策略，而RLI是这一普遍原理中最有效但也最具毒性的范例。
MEMBER ACCOUNT
登录成功会直接打开下一页。
